
Lumry discusses routine quality-of-life assessment, the pediatric HAE prophylaxis pipeline, and open questions after real-world lanadelumab data.

William Lumry, MD: Founder of the Allergy & Asthma Specialists of Dallas

Lumry discusses routine quality-of-life assessment, the pediatric HAE prophylaxis pipeline, and open questions after real-world lanadelumab data.

Caregiver-rated QoL rose from 1.9 to 4.5 on a 5-point scale with lanadelumab prophylaxis in a pediatric HAE registry analysis, William Lumry, MD, said.

William R. Lumry, MD, reports a 95% drop in attack frequency after lanadelumab initiation in a real-world chart review of 13 pediatric patients with HAE.

Donidalorsen demonstrates strong efficacy in patients switching from other HAE prophylactic treatments. Lumry discusses pivotal data after FDA approval.

Lumry discuses donidalorsen, the first FDA-approved, RNA-targeted therapy for hereditary angioedema.